Navigation Links
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Date:11/30/2007

ned to either Cymbalta at the same dose or to a sugar pill for 6 months. Patients on Cymbalta experienced a statistically longer time to relapse of depression than did patients on placebo. Relapse was defined as an increase of two or more points on the Clinical Global Impression - Severity scale (CGI-S) compared with that obtained at week 12, and also meeting the criteria for major depressive disorder for two consecutive visits.

In this study, nausea was the most frequently reported side effect (also referred to as a treatment-emergent adverse event) during the acute phase and was reported as a reason for discontinuation for 2.1 percent of patients. In the continuation phase, there were no significant differences in reported side effects between patients taking Cymbalta compared with those taking sugar pills. Among patients who completed the first 12 weeks of the trial and entered the continuation phase, 3.6 percent reported side effects as reasons for discontinuation over the next 26 weeks (continuation phase) of the study.(2)

Cymbalta, a member of a class of drugs commonly referred to as serotonin and norepinephrine reuptake inhibitors (SNRI), has been studied in more than 27,000 patients worldwide. Cymbalta is already approved for the acute treatment of major depressive disorder, the management of diabetic peripheral neuropathic pain, and for the treatment of generalized anxiety disorder, all in adults. More than 9 million adults in the United States have been prescribed Cymbalta since approval.

About Cymbalta

Serotonin and norepinephrine in the brain and spinal cord are believed to both mediate mood symptoms of depression and help regulate the perception of pain. Based on pre-clinical studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord). While the mechanism of action of duloxet
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015  Shareholder rights ... that a federal securities fraud class action complaint ... the Southern District of California.  The complaint alleges ... CLDN ) violated the Securities Exchange Act ... 25, 2015, by making materially false and misleading ...
(Date:7/7/2015)... 7, 2015 Berger & Montague, P.C., ... law firm with one of the largest and ... co-counsel Faruqi and Faruqi, LLP in settling three ... AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen, Inc., ... fees.  Under the agreements, AstraZeneca will pay the ...
(Date:7/7/2015)... Kalifornien, 7. Juli 2015 Sequent ... sich der Entwicklung innovativer Geräte für die ... Zugang von R. Michael Kleine ... Herr Kleine verfügt über eine mehr als ... Gesundheitsfürsorge. Er hat verschiedene globale biomedizinische Unternehmen ...
Breaking Medicine Technology:Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed Class Action 2Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed Class Action 3AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck 2AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck 3Sequent Medical beruft Mike Kleine in den Aufsichtsrat 2Sequent Medical beruft Mike Kleine in den Aufsichtsrat 3
... Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... MOUNTAIN VIEW, Calif., Sept. 21 VIVUS, Inc. (Nasdaq: ... from a two-year study of QNEXA® (phentermine/topiramate) Controlled Release ... condition that affects approximately one-third of adult Americans. ... (OB-305), a 52-week extension study for a subset of ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 2New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 4New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 5New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 6
(Date:7/7/2015)... NY (PRWEB) , ... July 08, 2015 , ... ... honors Jennifer Call as a 2015-2016 inductee into its VIP Woman of the ... health. NAPW is the nation’s leading networking organization exclusively for professional women, boasting ...
(Date:7/7/2015)... Rockville, MD (PRWEB) , ... July 08, 2015 ... ... educational event designed to help today’s surgical services directors and business managers increase ... OR Manager, the conference will be held at the Renaissance Phoenix Glendale, February ...
(Date:7/7/2015)... ... July 08, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... the nation’s leading networking organization exclusively for professional women, boasting more than 700,000 ...
(Date:7/7/2015)... ... ... The National Association of Professional Women (NAPW) honors Alyssa ... She is recognized with this prestigious distinction for leadership in pharmacy. NAPW is the ... over 200 operating Local Chapters. , “I’m pleased to recognize Alyssa with this important ...
(Date:7/7/2015)... (PRWEB) , ... July 08, 2015 , ... ... Jessica Goldstein as a 2015-2016 inductee into its VIP Woman of ... business. NAPW is the nation’s leading networking organization exclusively for professional women, boasting ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Jennifer Call, Clinical Director at Apex Behavior Consulting, Into its VIP Woman of the Year Circle 2Health News:Agenda, Pre-Conference Workshop, and More Announced for OR Business Management Conference 2Health News:Agenda, Pre-Conference Workshop, and More Announced for OR Business Management Conference 3Health News:National Association of Professional Women Inducts Brandy Emmons-Powell, Director of Quality Development at Didlake, Inc., Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Brandy Emmons-Powell, Director of Quality Development at Didlake, Inc., Into its VIP Woman of the Year Circle 3Health News:National Association of Professional Women Inducts Dr. Alyssa Greedy, Pharm. D., Pharmacy Manager at Walgreens, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Jessica Goldstein, Vice President / Account Director at Discovery USA, Into its VIP Woman of the Year Circle 2
... But sites devoted to complementary or alternative medicine may ... 11 (HealthDay News) -- Just 5 percent of Web ... pages focused on complementary or alternative medicine are 15 ... other false information, a new study says. , Moreover, ...
... DC When the public considers competing arguments about a ... agree with the expert whose values are closest to their ... will hold true for nanotechnology, a key study has found. ... today by the Project on Emerging Nanotechnologies (PEN). The study ...
... ... - $352 Average Patient Charge (APC) ... - $13.9 Million EBITDA From Continuing Operations ... 2008 Guidance, SCOTTSDALE, Ariz., Feb. 11 Rural/Metro,Corporation (Nasdaq: RURL ), a leading provider ...
... National Insurers Bring Programs to the State, While ... According to a New Report from HealthLeaders-InterStudy, ... of managed care market intelligence, reports that pay-for-,performance ... According to the,latest Arizona Health Plan Analysis, the ...
... recent years, increasing attention,has been paid to the ... In some instances, proponents of LBA made,overly-optimistic claims ... predictor in,the underwriting process. Milliman expert Jonathan Shreve, ... effective use of Lifestyle-Based,Analytics as an advance in ...
... SAN JUAN, Puerto Rico, Feb. 11 Triple-S,Management Corporation ... in,Puerto Rico, today announced record consolidated operating income of ... $2.15 for the year ended,December 31, 2007 (including $0.07 ... Company,s strong market position and medical cost,management., ...
Cached Medicine News:Health News:Most Breast Cancer Web Pages Contain Reliable Information 2Health News:Nanotechnology's future depends on who the public trusts 2Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 2Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 3Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 4Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 5Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 6Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 7Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 8Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 9Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 10Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 11Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 12Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 13Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 14Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 15Health News:Pay-For-Performance Not Getting a Red-Carpet Reception in Arizona 2Health News:Milliman Expert Addresses Practical Applications of Lifestyle-Based Analytics in Risk Selection 2Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 2Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 3Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 4Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 5Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 6Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 7Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 8Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 9Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 10Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 11Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 12Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 13
... system for performing fast, clean, safe and ... is microprocessor controlled to automatically spin CenSlide ... minute. At the end of the cycle, ... the viewing area for microscopic analysis.,The CenSlide ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
... temporary internal drainage from the ... Supplied sterile in peel-open packages. ... Periodic evaluation is advised; polyurethane, ... not remain indwelling more than ...
... temporary internal drainage from ... the bladder in pediatric ... peel-open packages. Intended for ... evaluation is advised; stent ...
Medicine Products: